Can a quick dose of dapagliflozin help elderly heart failure patients in the ER?
NCT ID NCT07392788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether starting the drug dapagliflozin within 24 hours of arriving at the emergency room is practical for elderly patients (75+) with acute heart failure. It will involve 144 patients across 6 hospitals, comparing early drug treatment plus a nurse phone call to standard care alone. The main goal is to see if the process works smoothly, not yet to measure health benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a type of SGLT2 inhibitor drug)
What this could lead to
If successful, this could show that starting dapagliflozin early in the emergency room is practical for elderly heart failure patients, potentially leading to better outcomes.
What could go wrong
This is a small pilot study focused on feasibility, not effectiveness. It may not prove that early treatment improves health, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HEART FAILURE (AHF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••